28
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Epidemiology and Health Impacts of Neuroendocrine Tumors

      Submit here before August 30, 2024

      About Neuroendocrinology: 3.2 Impact Factor I 8.3 CiteScore I 1.009 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Neuroinflammation: A Common Pathway in CNS Diseases as Mediated at the Blood-Brain Barrier

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The blood-brain barrier (BBB) is not simply a physical barrier but a regulatory interface between the central nervous system (CNS) and immune system. The BBB both affects and is affected by the immune system and connects at many levels with the CNS, including the following: (1) the BBB transports cytokines and secretes various substances with neuroinflammatory properties; (2) transporters are altered in disease states including traumatic injury, Alzheimer’s disease and inflammatory processes; (3) cytokines and other immune secretions from the cells comprising the BBB are both constitutive and inducible; (4) immune cells are transported across the BBB by the highly regulated process termed diapedesis, which involves communication and interactions between the brain endothelial cells and the immune cells; (5) the neuroimmune system has various effects on the BBB, including modulation of important transport systems and in extreme pathological conditions even disruption of the BBB, and (6) the brain-to-blood efflux transporter P-glycoprotein is altered in inflammatory conditions, thus affecting drug delivery to the brain. In summary, the BBB is an interactive interface that regulates and defines many of the ways that the CNS and the immune system communicate with one another.

          Related collections

          Author and article information

          Journal
          NIM
          Neuroimmunomodulation
          10.1159/issn.1021-7401
          Neuroimmunomodulation
          S. Karger AG
          1021-7401
          1423-0216
          2012
          January 2012
          11 January 2012
          : 19
          : 2
          : 121-130
          Affiliations
          aGeriatrics Research Education and Clinical Center, Puget Sound Health Care System, bDivision of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington School of Medicine, Seattle, Wash., and cDepartment of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, Mo., USA; dDepartment of Emergency and Critical Care Medicine, Showa University School of Medicine, Tokyo, Japan
          Author notes
          *William A. Banks, 810A/1, VAPSHCS, 1660 S. Columbian Way, Seattle, WA 98108 (USA), Tel. +1 206 764 2701, E-Mail wabanks1@uw.edu
          Article
          330247 PMC3707010 Neuroimmunomodulation 2012;19:121–130
          10.1159/000330247
          PMC3707010
          22248728
          d0fc60df-f7e7-4469-ad54-01b3f535c8ef
          © 2012 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 09 March 2011
          : 22 June 2011
          Page count
          Figures: 2, Pages: 10
          Categories
          Review

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Cytokines,Blood-brain barrier,P-glycoprotein,Transport,Alzheimer’s disease,Neuroinflammation,Drug delivery

          Comments

          Comment on this article